Hypothesis

Partial cyclic expression of Yamanaka factors (OSK) in aged neurons restores youthful microglial pruning behavior by directly resetting the epigenetic state of complement component 1q (C1q) and the "don't-eat-me" signal CD47 in microglia, thereby shifting the C1q/CD47 ratio back to youthful levels and preventing excessive synapse loss.

Mechanistic rationale

• Yamanaka factors recruit histone deacetylases and DNA demethylases to promoters of immune‑related genes.
• In microglia, OSK‑induced expression of the transcriptional repressor REST silences C1q transcription through increased H3K9me3 deposition at its enhancer.
• Simultaneously, OSK activates enhancer regions upstream of CD47 via increased H3K27ac, boosting CD47 surface expression.
• The combined effect lowers the microglial "eat-me" signal while raising the "don't-eat-me" signal, moving the phagocytic threshold toward that observed in young brains.

Testable predictions

1. Molecular – Aged mice receiving intermittent OSK (e.g., doxycycline‑inducible OSK 2 days/week) will show:

   • ↓ C1q mRNA and protein in microglia isolated from cortex and hippocampus.
   • ↑ CD47 mRNA and protein in the same microglial population.
   • No change in total microglial number or proliferation marker Ki67.

2. Synaptic – Same mice will exhibit:

   • Higher synaptic density (synaptophysin/PSD95 puncta) compared with vehicle‑treated aged controls.
   • Preservation of dendritic spine length and branching.

3. Behavioral – Improved performance in hippocampal‑dependent tasks (e.g., Morris water maze, novel object recognition) correlating with the magnitude of C1q/CD47 reversal.

Experimental design (brief)

• Animals: 20‑month‑old C57BL/6J mice, both sexes, n=10 per group.
• Intervention: Doxycycline‑inducible OSK transgene activated 2 days on/5 days off for 8 weeks.
• Controls: Age‑matched littermates with transgene but no doxycycline; young (3‑month) baseline.
• Readouts: Flow cytometry for C1q and CD47 on CD11b^+ microglia; immunoblot; immunostaining for synaptic markers; behavioral testing weeks 7‑8.
• Statistical analysis: Two‑way ANOVA (age × treatment) with post‑hoc Tukey; significance set at p<0.05.

Falsifiability

If OSK does not significantly alter microglial C1q or CD47 expression, or if synaptic density and cognitive performance remain unchanged despite neuronal epigenetic rejuvenation, the hypothesis that partial reprogramming rescues pruning thresholds via the C1q/CD47 axis would be refuted. Conversely, a selective reset of these molecules without affecting other inflammatory pathways would support the mechanistic link.

Broader implication

Restoring youthful synaptic quality control may uncouple neuronal health from network decay, suggesting that therapies targeting microglial epigenetic state could complement neuroregenerative strategies in age‑related cognitive decline.